Nadolol
As of the edition of 20 October 2026, Nadolol is a small molecule: marketed, first approved in 1980 (FR); acts on ADRB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Corgard
- First approved
- 3 July 1980 (FR)
- Approvals on record
- 8 in 2 regions
- Holder of the most recent approval
- Uswm; 3 holders in all
- Registered trials
- 10, 0 stopped early
- Disease areas
- Nervous system; Cancer; Digestive system; Heart and blood vessels; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 5 | 4 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Uswm | Acquired holder | 2020 to now |
| Bristol Myers Squibb | Earlier holder |